Top news of the week: 29.06.2022.
New Technology Helps Reveal Inner Workings of Human Genome
Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the ...
Chinese biotech Therorna completes $42M series A to develop circRNA COVID-19 vaccines
Chinese biotech company Therorna Inc. completed a $42 million series A round to develop its circular RNA (circRNA) vaccines and therapies.
Ipsen beefs up in oncology, buying US biopharma Epizyme
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its
A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser
Investing (or trading) in small-cap biotech stocks, particularly without subject matter expertise, carries the same risk as walking through an active minefield. Inevitably, you can blow up.
Go ask Alice: Eat me and don’t eat me signals at the heart of DEM Biopharma
Despite a huge amount of progress in the hot space CD47, there’s a large space beyond it to explore, according to DEM Biopharma Inc.’s CEO David Donabedian. The new company just raised $70 ...
Astellas pumps $90m into Sutro immuno-oncology alliance
Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates
Astellas and Sutro Unite to Overcome Checkpoint Inhibitor Limitations with iADCs
Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.
Earlham Biofoundry
The Earlham Biofoundry is a resource for the UK biology and biotechnology communities, providing a platform to undertake large-scale projects.